Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2017
Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer
M Suenaga, M Schirripa, S Cao, et al.
The Pharmacogenomics Journal
|
October 5, 2016
A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials
A Sebio, S Stintzing, V Heinemann, et al.
The Pharmacogenomics Journal
|
October 28, 2015
Estrogen receptor-beta genetic variations and overall survival in patients with locally advanced gastric cancer
Y Sunakawa, S Cao, M D Berger, et al.
The Pharmacogenomics Journal
|
April 12, 2017
Prognostic impact of FOXF1 polymorphisms in gastric cancer patients
S Matsusaka, A H Wu, S Cao, et al.
The Pharmacogenomics Journal
|
June 1, 2016
Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer
Y Sunakawa, S Cao, N B Volz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2015
Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials
Y Sunakawa, S Stintzing, S Cao, et al.
The Pharmacogenomics Journal
|
December 23, 2015
Genetic variants associated with colorectal brain metastases susceptibility and survival
S Stremitzer, A S Berghoff, N B Volz, et al.
ESMO Open
|
March 2, 2023
Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases
J R Hecht, S S Raman, A Chan, et al.
The Pharmacogenomics Journal
|
August 10, 2016
CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy
S Matsusaka, S Cao, D L Hanna, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2017
Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer
M Suenaga, M Schirripa, S Cao, et al.
The Pharmacogenomics Journal
|
October 5, 2016
A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials
A Sebio, S Stintzing, V Heinemann, et al.
The Pharmacogenomics Journal
|
October 28, 2015
Estrogen receptor-beta genetic variations and overall survival in patients with locally advanced gastric cancer
Y Sunakawa, S Cao, M D Berger, et al.
The Pharmacogenomics Journal
|
April 12, 2017
Prognostic impact of FOXF1 polymorphisms in gastric cancer patients
S Matsusaka, A H Wu, S Cao, et al.
The Pharmacogenomics Journal
|
June 1, 2016
Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer
Y Sunakawa, S Cao, N B Volz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2015
Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials
Y Sunakawa, S Stintzing, S Cao, et al.
The Pharmacogenomics Journal
|
December 23, 2015
Genetic variants associated with colorectal brain metastases susceptibility and survival
S Stremitzer, A S Berghoff, N B Volz, et al.
ESMO Open
|
March 2, 2023
Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases
J R Hecht, S S Raman, A Chan, et al.
The Pharmacogenomics Journal
|
August 10, 2016
CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy
S Matsusaka, S Cao, D L Hanna, et al.
Page
of 2